daunorubicin + vincristine + cyclophosphamide + l-asparaginase + dexamethasone

This is a combination chemotherapy regimen that includes **daunorubicin**, **vincristine**, **cyclophosphamide**, **l-asparaginase**, and **dexamethasone**, most commonly used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric and adult induction protocols. The regimen combines several cytotoxic agents with different mechanisms of action to achieve synergistic antileukemic effects: - **Daunorubicin** is an anthracycline that intercalates into DNA, inhibiting topoisomerase II and generating free radicals, leading to DNA damage. - **Vincristine** is a vinca alkaloid that disrupts microtubule assembly, inhibiting mitosis. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA. - **L-asparaginase** depletes asparagine, an amino acid needed by leukemic cells. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and cytotoxic activity towards lymphoid cells. This combination exploits different vulnerabilities of leukemic cells and is used for remission induction[1][5][6].